Google
Trusted Resources: News & Events
Latest announcements and gatherings
Siklos (hydroxyurea) now available through ProCare Pharmacy Care’s Siklos At Home program
Medunik USA announced today that Siklos® (hydroxyurea), the first and only hydroxyurea-based treatment FDA-approved for pediatric patients with sickle cell anemia, is now available through the Siklos At Home™ program.
“The recent launch of Siklos® represents an important milestone in Medunik USA’s mission to support patients with rare diseases – in this case, sickle cell anemia,” said Dean Hopkins, the company’s General Manager. “We are looking forward to introducing this treatment to pediatric patients with sickle cell anemia and committed to providing Siklos® at the lowest possible cost to all patients, whether they are cash-paying or have commercial or Medicaid healthcare coverage, through the Siklos At Home™ program, offered through our specialty pharmacy, ProCare Pharmacy Care.”
Through Siklos At Home™, commercially insured patients can receive Siklos® for as little as $0 copay per prescription. Patients who are not insured or whose insurance does not cover Siklos® can pay as little as $99 for 60 tablets or $149 for 90 tablets.
+myBinderRelated Content
-
Effort set to help sickle cell patients manage medsVanderbilt University Medical Center is ...
-
Treating sickle cell disease: Is hydroxyurea right for you?Sickle cell disease changes the shape an...
-
Hydroxycarbamide treatment and brain MRI/MRA findings in children with sickle cell anaemiaSilent cerebral infarction (SCI) is the ...
-
Sickle Cell Disease, Hydroxyurea: What You Should Knowhttps://www.onescdvoice.com/wp-content/u...
-
A Conversation on Hydroxyurea: Insights and Information for the Sickle Cell Communityhttps://www.youtube.com/watch?v=Y6fmJn-5...
-
FDA Approves Hydroxyurea Tablets for Pediatric Patients With Sickle Cell AnemiaThe US Food and Drug Administration (FDA...
-
Discovery could help treatments for sickle cell diseaseResearch team establishes biomarkers for...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.